Misplaced Pages

Birabresib

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (April 2023)
Pharmaceutical compound
Birabresib
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • 2- triazolo diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC25H22ClN5O2S
Molar mass491.99 g·mol
3D model (JSmol)
SMILES
  • CC1=C(SC2=C1C(=N(C3=NN=C(N32)C)CC(=O)NC4=CC=C(C=C4)O)C5=CC=C(C=C5)Cl)C
InChI
  • InChI=1S/C25H22ClN5O2S/c1-13-14(2)34-25-22(13)23(16-4-6-17(26)7-5-16)28-20(24-30-29-15(3)31(24)25)12-21(33)27-18-8-10-19(32)11-9-18/h4-11,20,32H,12H2,1-3H3,(H,27,33)/t20-/m0/s1
  • Key:GNMUEVRJHCWKTO-FQEVSTJZSA-N

Birabresib (OTX-015, MK-8628) is an experimental small molecule inhibitor of BRD2, BRD3, and BRD4 under investigation for the treatment of cancer. It is in development by Merck & Co. It is currently in clinical trials for leukemia and glioblastoma.

References

  1. "Birabresib" (PDF). Statement on a Nonproprietary Name Adopted by the USAN Council.
  2. "Birabresib - OncoEthix". AdisInsight. Springer Nature Switzerland AG.
Category:
Birabresib Add topic